New selective and allosteric FLT3 inhibitors show efficacy against resistant acute myeloid leukemia cells
Authors:
Open Access
Abstract
No abstract availableKeywords
Funding Information
- National Natural Science Foundation of China (82470224)
- National Natural Science Foundation of China (82270165)
- National Natural Science Foundation of China (82200227)
- Major Basic Research Project of the Natural Science Foundation of the Jiangsu Higher Education Institutions (szWzy202406)
- Major Basic Research Project of the Natural Science Foundation of the Jiangsu Higher Education Institutions (24KJA310008)
- Natural Science Foundation of Jiangsu Province (BK20221235)
- Government of Jiangsu Province
This publication has 50 references indexed in Scilit:
- Overcoming cancer therapy resistance: From drug innovation to therapeuticsDrug Resistance Updates, 2025
- Properties of FDA-approved small molecule protein kinase inhibitors: A 2024 updatePharmacological Research, 2024
- Sorafenib maintenance after allogeneic haemopoietic stem-cell transplantation in patients with FLT3-ITD acute myeloid leukaemia: long-term follow-up of an open-label, multicentre, randomised, phase 3 trialThe Lancet Haematology, 2023
- Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trialThe Lancet, 2023
- Acute myeloid leukaemiaThe Lancet, 2023
- Asciminib: First ApprovalDrugs, 2022
- A Selective Small Molecule DNA2 Inhibitor for Sensitization of Human Cancer Cells to ChemotherapyEBioMedicine, 2016
- Classification of small molecule protein kinase inhibitors based upon the structures of their drug-enzyme complexesPharmacological Research, 2016
- Purification of His-Tagged Proteins2015
- The Structural Basis for Autoinhibition of FLT3 by the Juxtamembrane DomainMolecular Cell, 2004